Skylabs Opens 16.70% Lower on First Day of KOSDAQ Listing... IPO Price at 10,000 Won, Wearable Medical Device Firm
Digital healthcare company Skylabs debuted on the KOSDAQ market on the 4th, starting with a decline. As of 9 a.m. that day, the stock price stood at 8,330 won, down 16.70% from the final IPO price. Skylabs is a company that operates a business of continuously measuring and managing the vital signs

Digital healthcare company Skylabs debuted on the KOSDAQ market on the 4th, starting with a decline. As of 9 a.m. that day, the stock price stood at 8,330 won, down 16.70% from the final IPO price.
Skylabs is a company that operates a business of continuously measuring and managing the vital signs of chronic disease patients outside hospitals based on wearable medical devices. Attention is focused on how the market will evaluate the company following its listing.
■ IPO Price Set at 10,000 Won... Finalized Below Low End of Desired Range
According to corporate disclosure materials released on the 3rd, Skylabs' final IPO price is 10,000 won. The number of shares offered is 2 million, bringing the total offering amount to 20 billion won.
The company initially presented a desired IPO price range of 13,000 to 16,000 won, but the final price was set at 10,000 won, below the low end of the desired range.
The demand forecasting for institutional investors was conducted from August 14 to 21, recording a competition ratio of 63.41 to 1. Subsequently, the combined competition ratio for general investor subscriptions, conducted through Korea Investment & Securities from August 26 to 27, was tallied at 2.85 to 1. The total number of subscription applications was 16,152, with a proportional allocation competition ratio of 4.7 to 1.
The allocation announcement and payment/refund procedures were completed on August 31, with trading on the KOSDAQ market scheduled to begin on September 4.
■ Patient Monitoring Medical Devices as Core Products... CEO Lee Byung-hwan Holds 23% Stake
Founded in September 2015, Skylabs is a medical device manufacturer whose main products are patient monitoring medical devices. The CEO is Lee Byung-hwan, who is also the largest shareholder with a 23% stake.
The company develops, manufactures, and sells wearable medical devices and data platforms that can continuously measure, analyze, transmit, and manage the vital signs of chronic disease patients outside hospitals.
Noting the limitations of hospital-centered care environments, where medical staff cannot continuously monitor patients' conditions, the core of the business is building an environment in which patients' biometric data can be collected and managed in daily life.
■ Full-Scale Corporate Valuation Begins on Listing Day... Early Supply and Demand a Variable
On the first day of listing, a full-scale market evaluation of the company's value is expected to take place based on the final IPO price of 10,000 won. In particular, as the IPO price was set below the desired range and the general subscription competition ratio recorded 2.85 to 1, early supply and demand and trading volume are expected to be key variables for the stock price trend.
[This article is an informational piece based on publicly available market information and materials, and does not recommend the purchase, sale, or holding of any specific stock. Stock investments may result in loss of principal, and the final investment decision and responsibility rest with the investor. This article was written with AI assistance.]
CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.



